Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in the development of RNA interference (RNAi) therapeutics for the treatment of genetic and other diseases. The company's cutting-edge approach to drug development involves targeting specific genes and silencing them using RNAi technology. Alnylam's extensive pipeline includes potential treatments for a wide range of diseases, including rare genetic disorders, cardiovascular disease, and cancer. The company is dedicated to research and development, with a team of world-class scientists committed to discovering new therapies and advancing the field of RNAi. Headquartered in Cambridge, Massachusetts, Alnylam has a global presence with operations in Europe and Asia. The company is deeply committed to improving the lives of patients through the development of innovative and effective treatments.